MAIA Biotechnology
MAIA
20 hedge funds and large institutions have $2.26M invested in MAIA Biotechnology in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 3 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0% more funds holding
Funds holding: 20 → 20 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.32% less ownership
Funds ownership: 5.32% → 4.99% (-0.32%)
18% less capital invested
Capital invested by funds: $2.75M → $2.26M (-$493K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$125K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$80.4K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$31.3K |
| 4 |
NW
Naviter Wealth
Little Rock,
Arkansas
|
+$18.5K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$12.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$77.3K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$18K |
| 3 |
HFF
Halter Ferguson Financial
Carmel,
Indiana
|
-$6.41K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.64K |
MAIA Hedge Fund Activity: Q1 2025 in Review
20 of the 7,473 institutional investors tracked by Wall St. Rank reported a position in MAIA Biotechnology (MAIA) for Q1 2025, worth a combined $2.26M — down 18% from $2.75M a quarter earlier.
Fund positioning in MAIA was balanced in Q1 2025: 3 funds opened new positions, 3 closed out, 6 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $125K. The largest seller was Jane Street, exiting entirely with an estimated $77.3K sold.
- 20 institutional investors held MAIA Biotechnology (MAIA) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $2.26M of MAIA Biotechnology stock for Q1 2025, down 18% quarter-over-quarter.
- 3 funds opened new MAIA Biotechnology positions in Q1 2025 and 3 closed out, a net change of 0 holders.
- The largest MAIA Biotechnology buyer in Q1 2025 was Vanguard Group, an estimated $125K added.
- The largest MAIA Biotechnology seller in Q1 2025 was Jane Street, an estimated $77.3K sold.
Based on aggregated 13F filings for Q1 2025.